MCTW
XVIII. Myeloma and VI. Cell Therapy Workshop 2023
About the workshop
Key deadlines
- Registration Deadline: 15 September 2023
- Poster Abstract Submission Deadline: 15 September 2023
Registration
Registration fees
-
Passive on-site participation: 1200 Kč
-
Active on-site participation (oral presentation, poster section): free of charge
-
On-line participation: 1200 Kč
Program of the event
Even this year, MCTW will have its poster session! Posters will be scored by the panel of judges and the most successful three posters will be awarded as follows:
1st place: 500 euros
2nd place: 300 euros
3rd place: 200 euros
The poster should be in English and should be on the topic of hematological malignancies (basic, applied, or translational research, or clinical report/study).
All abstracts must fulfill the requirements stated in the document below and be submitted in the abstract submission template format (abstract submission template provided below).
Deadline for abstract submission: 15.9.2023
The decision on whether your abstract has been accepted for the poster session will be delivered to you by email with further instructions. If the poster is accepted for the poster session, it is obligatory to display it onsite, printed in format 120x90 cm (h x w).
Venue
Hornopolní 3313/42,
702 00 Moravská Ostrava a Přívoz,
Czech Republic
Organizers
prof. Roman Hájek, MD, Ph.D.
Michal Šimíček, Ph.D.
Past MCTWs in OSTRAVA
XVI. Multiple myeloma and IV. Cell therapy workshop, Ostrava (Czech Republic)
XV. Multiple Myeloma and III Cell Therapy Workshop, Ostrava (Czech Republic)
XIV. Multiple myeloma and II. Cell therapy workshop, Ostrava (Czech Republic)
Previous International Speakers
Pieter Sonneveld (Rotterdam, Netherlands)
Hermann Einsele (Wurzburg, Germany)
Sebastian Giebel (Gliwice, Poland)
Da Vià Matteo Claudio (Milan, Italy)
Bruno Paiva (Pamplona, Spain)
Tom Cupedo (Rotterdam, Netherland)
Cirino Botta (Palermo, Italy)
Francesco Maura (Miami, USA)
Caroline Heckman (Helsinki, Finland)
Kenneth C. Anderson (Boston USA)
and many more...
Acknowledgments
We want to thank the Department of Haematooncology (University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Czech Republic), Czech Myeloma Group, and our sponsors for their continued support.
Sponsors